Short Interest in Aptorum Group Limited (NASDAQ:APM) Decreases By 51.3%

Aptorum Group Limited (NASDAQ:APM) was the recipient of a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 110,800 shares, a decrease of 51.3% from the September 15th total of 227,700 shares. Based on an average daily volume of 9,770,000 shares, the short-interest ratio is currently 0.0 days. Approximately 2.6% of the shares of the company are short sold. Approximately 2.6% of the shares of the company are short sold. Based on an average daily volume of 9,770,000 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Aptorum Group in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Aptorum Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Aptorum Group currently has an average rating of “Sell”.

Aptorum Group Stock Performance

Aptorum Group stock opened at $1.60 on Wednesday. The firm has a 50 day simple moving average of $1.90 and a 200-day simple moving average of $1.37. Aptorum Group has a 12-month low of $0.46 and a 12-month high of $7.49.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.